[go: up one dir, main page]

AR130877A1 - N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estas - Google Patents

N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estas

Info

Publication number
AR130877A1
AR130877A1 ARP230102864A ARP230102864A AR130877A1 AR 130877 A1 AR130877 A1 AR 130877A1 AR P230102864 A ARP230102864 A AR P230102864A AR P230102864 A ARP230102864 A AR P230102864A AR 130877 A1 AR130877 A1 AR 130877A1
Authority
AR
Argentina
Prior art keywords
dmt
composition
dimethyltryptamine
amorphous
polymeric carrier
Prior art date
Application number
ARP230102864A
Other languages
English (en)
Spanish (es)
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/974,443 external-priority patent/US20230136824A1/en
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of AR130877A1 publication Critical patent/AR130877A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP230102864A 2022-10-26 2023-10-26 N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estas AR130877A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17/974,443 US20230136824A1 (en) 2021-04-26 2022-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof

Publications (1)

Publication Number Publication Date
AR130877A1 true AR130877A1 (es) 2025-01-29

Family

ID=90832092

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102864A AR130877A1 (es) 2022-10-26 2023-10-26 N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estas

Country Status (6)

Country Link
EP (1) EP4608395A2 (fr)
AR (1) AR130877A1 (fr)
AU (1) AU2023367107A1 (fr)
CA (1) CA3267555A1 (fr)
TW (1) TW202423415A (fr)
WO (1) WO2024092106A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182156A1 (fr) 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matiere et compositions pharmaceutiques
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021003467A1 (fr) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Compositions de dosage et procédés d'utilisation de composés psychédéliques
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
CA3182156A1 (fr) * 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matiere et compositions pharmaceutiques
EP3941904A1 (fr) * 2020-06-12 2022-01-26 Beckley Psytech Limited Composition pharmaceutique comprenant de la 5-méthoxy-n, n-diméthyltryptamine
CA3192617A1 (fr) * 2020-09-20 2022-03-24 Matthew BAGGOTT Compositions de tryptamine avantageuses pour troubles mentaux ou amelioration mentale
BR112023022195A2 (pt) * 2021-04-26 2024-01-16 Atai Therapeutics Inc Novas composições e métodos de n,n-dimetiltriptamina

Also Published As

Publication number Publication date
EP4608395A2 (fr) 2025-09-03
TW202423415A (zh) 2024-06-16
AU2023367107A1 (en) 2025-03-27
CA3267555A1 (fr) 2024-05-02
WO2024092106A3 (fr) 2024-06-06
WO2024092106A2 (fr) 2024-05-02

Similar Documents

Publication Publication Date Title
AR130877A1 (es) N-n-dimetiltriptamina (dmt) y composiciones análogas de dmt, métodos de fabricación y métodos de uso de estas
US11806347B2 (en) Transmucosal methods for treating psychiatric and neurological conditions
EP1408034B2 (fr) Utilisation des dérivés des quinolones et quinolizinones comme agents chemothérapeutiques
US5900247A (en) Mucoadhesive pharmaceutical composition for the controlled release of active principles
CA2751884C (fr) Administration transdermique de tamsulosine
EP3843729A1 (fr) Nouvelles compositions et méthodes
US20130310462A1 (en) Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
JPH06305958A (ja) 消炎鎮痛外用貼付剤
AU7723894A (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
CA2784587A1 (fr) Formes pharmaceutiques se presentant sous la forme de films administrables par voie orale contenant de l'ondansetron
US11738006B2 (en) Pharmaceutical composition containing antifungal agent as active ingredient
Mishra et al. Plasticizers: A vital excipient in novel pharmaceutical formulations
Nair et al. Mucoadhesive buccal patch of cefixime trihydrate using biodegradable natural polymer
US20050214230A1 (en) Novel stomatological gel
Pv et al. Formulation design and evaluation of bilayer buccal tablets of granisetron hydrochloride
IE60458B1 (en) Enhanced bioavailability adsorbates
US20230331762A1 (en) Crystalline form of aspacytarabine
KR20020012978A (ko) 진통소염 효과를 갖는 디클로페낙염을 함유 카타플라스마제
GB2173101A (en) Dopaminergic composition containing dihydroergocryptine
KR102860999B1 (ko) 졸피뎀 또는 이의 약제학적으로 허용되는 염의 구강점막 용액
WO2025110709A1 (fr) Composition pour la prévention ou le traitement d'une maladie parodontale et composition d'onguent antibiotique composite dentaire
RO137880A2 (ro) Compoziţie de sistem mucoadeziv pentru eliberarea topică a doxicilinei la nivelul cavităţii orale
US20130184239A1 (en) Combination of siloxane and active ingredient for treating dental disorder
Willcox Treatment implications of the lessened sensitivity of the gonococcus to penicillin
WO2025230326A1 (fr) Composition ophtalmique comprenant de la pilocarpine